East China Pharmaceutical: Exclusive distribution product injection of recombinant type A botulinum toxin approved for listing.

East China Pharmaceutical announced that the company has obtained approval from the National Medical Products Administration to market exclusively the injection of recombinant type A botulinum toxin for the temporary improvement of moderate to severe glabellar lines caused by the activity of the corrugator muscle and/or procerus muscle in adults 65 years of age and younger.